TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03656991

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Bicycle intervention

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Bicycle intervention

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Bicycle intervention

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Bicycle intervention
Study: NCT00511238

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carfilzomib
Description: Subjects will receive carfilzomib 20 mg/m2 as an intravenous bolus over 2 minutes on Days 1, 2, 8, 9, 15, and 16 of 28 day cycles. A maximum of 12 cycles will be administered.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carfilzomib
Description: Subjects will receive carfilzomib intravenously over up to 10 minutes on Days 1, 2, 8, 9, 15, and 16 of 28 day cycles. In cycle 1, the dose is 20 mg/m2. If all doses are administered and well-tolerated over Cycle 1, beginning with Cycle 2 the dose will escalate to 27 mg/m2 cycle. A maximum of 12 cycles will be administered.
Study: NCT04503720

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CLoWI
Description: Patients will receive a continuous wound infusion with ropivacaine and normal saline in the PCA pump.
Study: NCT00225381

Intervention type: DEVICE
Intervention: A mixing chamber (bymixer)
Description: 2 mixing chambers (bymixers) composed of 2 arms where one arm serves as a mixing (passive) arm for the measurement of mixed gas fraction. The bymixer is made of conventional anesthesia supplies and does not influence dead space nor circuit resistance.

Intervention type: DEVICE
Intervention: A mixing chamber (bymixer)
Description: 2 mixing chambers (bymixers) composed of 2 arms where one arm serves as a mixing (passive) arm for the measurement of mixed gas fraction. The bymixer is made of conventional anesthesia supplies and does not influence dead space nor circuit resistance.

Intervention type: DEVICE
Intervention: A mixing chamber (bymixer)
Description: 2 mixing chambers (bymixers) composed of 2 arms where one arm serves as a mixing (passive) arm for the measurement of mixed gas fraction. The bymixer is made of conventional anesthesia supplies and does not influence dead space nor circuit resistance.

Intervention type: DEVICE
Intervention: Pneumotachometer cuvette
Description: The pneumotachometer cuvette is used by many anesthesia monitors to measure gas flow.

Intervention type: DEVICE
Intervention: Pneumotachometer cuvette
Description: The pneumotachometer cuvette is used by many anesthesia monitors to measure gas flow.

Intervention type: DEVICE
Intervention: Pneumotachometer cuvette
Description: The pneumotachometer cuvette is used by many anesthesia monitors to measure gas flow.

Intervention type: DEVICE
Intervention: Pneumotachometer cuvette
Description: The pneumotachometer cuvette is used by many anesthesia monitors to measure gas flow.

Intervention type: DEVICE
Intervention: Pneumotachometer cuvette
Description: The pneumotachometer cuvette is used by many anesthesia monitors to measure gas flow.

Intervention type: DEVICE
Intervention: Mass spectrometer sampling port
Description: Designed for the anesthesia tubing and connected at the airway opening. it has small volume (3 mL) and do not influence circuit resistance.
Study: NCT01373749

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: NO inhalation
Description: NO inhalation was performed as the only treatment for PPHN during the whole course.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NO inhalation continued with sildenafil
Description: NO inhalation was performed as the primary treatment for PPHN in the first 48 hours, NO inhalation will be replaced by sildenafil after 48 hours of therapy.
Study: NCT04503720

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: PCA
Description: Patients will receive a continuous wound infusion with normal saline and morphine in the PCA pump.
Study: NCT01450098

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2484595 Reference Formulation (RF)
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2484595 spray-dried solid dispersion-propyl gallate (SDSD-PG)
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2484595 spray-dried solid dispersion-propyl gallate (SDSD-PG)
Description: Administered orally
Study: NCT04164290

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Jiashen Tablets
Description: 1 tablet

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Jiashen Tablets
Description: 2 tablets

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Jiashen Tablets
Description: 4 tablets
Study: NCT04407741

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR2554+SHR1701
Description: SHR2554: recommended dose from phase I trial, PO, twice a day. SHR1701: 30mg/kg, IV, over 30 minutes
Study: NCT04164290

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Jiashen Tablets
Description: 6 tablets

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Jiashen Tablets
Description: 8 tablets

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Jiashen Tablets
Description: 9 tablets

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Jiashen Tablets Placebo
Description: 1 tablet

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Jiashen Tablets Placebo
Description: 2 tablets

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Jiashen Tablets Placebo
Description: 4 tablets

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Jiashen Tablets Placebo
Description: 6 tablets

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Jiashen Tablets Placebo
Description: 8 tablets

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Jiashen Tablets Placebo
Description: 9 tablets
Study: NCT03632213

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Losartan
Description: Losartan group: 15 patients, both sexes, will receive Losartan 0.4 to 1.4 mg/kg/day orally for 12 months.
Study: NCT04407741

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR1701
Description: SHR1701: 30mg/kg, IV, over 30 minutes
Study: NCT02363465

Intervention type: OTHER
Intervention: Echographic measurement of skin thickness
Description: (Epi)Dermal thickness at the proximal forearm and the deltoid region will be measured using imaging technology, more specifically high-frequency ultrasound (20-40 MHz) in B-mode (VEVO 2100®, Visual Sonics). This non-invasive measuring technique has already been proven to be accurate.~The echographic measurement will be performed on the left and right deltoid region and on two sides of the proximal forearm. Both the dorsal part and the volar/palmar part of the proximal forearm will be investigated. Ultrasound will be executed using gel (Aquasonic®) to optimize imaging.

Intervention type: OTHER
Intervention: Echographic measurement of skin thickness
Description: (Epi)Dermal thickness at the proximal forearm and the deltoid region will be measured using imaging technology, more specifically high-frequency ultrasound (20-40 MHz) in B-mode (VEVO 2100®, Visual Sonics). This non-invasive measuring technique has already been proven to be accurate.~The echographic measurement will be performed on the left and right deltoid region and on two sides of the proximal forearm. Both the dorsal part and the volar/palmar part of the proximal forearm will be investigated. Ultrasound will be executed using gel (Aquasonic®) to optimize imaging.

Intervention type: OTHER
Intervention: Echographic measurement of skin thickness
Description: (Epi)Dermal thickness at the proximal forearm and the deltoid region will be measured using imaging technology, more specifically high-frequency ultrasound (20-40 MHz) in B-mode (VEVO 2100®, Visual Sonics). This non-invasive measuring technique has already been proven to be accurate.~The echographic measurement will be performed on the left and right deltoid region and on two sides of the proximal forearm. Both the dorsal part and the volar/palmar part of the proximal forearm will be investigated. Ultrasound will be executed using gel (Aquasonic®) to optimize imaging.
Study: NCT03632213

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo group: 15 patients, both sexes, will receive oral placebo for 12 months.
Study: NCT03268941

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-906 Maleate
Description: TAK-906 Maleate Capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-906 Maleate
Description: TAK-906 Maleate Capsules
Study: NCT02656069

Intervention type: DRUG
Group type: OTHER
Intervention: G-Pen (glucagon injection)
Description: 1 mg of pre-mixed liquid Xeris glucagon delivered via auto-injector

Intervention type: DRUG
Group type: OTHER
Intervention: G-Pen (glucagon injection)
Description: 1 mg of pre-mixed liquid Xeris glucagon delivered via auto-injector

Intervention type: DRUG
Group type: OTHER
Intervention: Lilly Glucagon (glucagon injection [rDNA origin])
Description: 1 mg of Lilly glucagon reconstituted from lyophilized powder

Intervention type: DRUG
Group type: OTHER
Intervention: Lilly Glucagon (glucagon injection [rDNA origin])
Description: 1 mg of Lilly glucagon reconstituted from lyophilized powder
Study: NCT03268941

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-906 Maleate
Description: TAK-906 Maleate Capsules
Study: NCT03353701

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Contingency Management (CM)
Description: A reinforcement delivery method that involves financial incentive to participants for sustained alcohol abstinence. CM will start after the participants complete the baseline measures and last for at least 30 days and up to 90 days.
Study: NCT01029743

Intervention type: DRUG
Intervention: Rivaroxaban (Xarelto, BAY59-7939)
Description: Daily dose, a treatment duration of 5 weeks for patients undergoing major hip surgery and a treatment duration of 2 weeks for patients undergoing major knee surgery are recommended

Intervention type: DRUG
Intervention: Pharmacologic agents (e.g. LMWH/VKA/Fondaparinux/Aspirin and etc.)
Description: Daily dose, dosage frequency and duration will be decided by physicians
Study: NCT00932672

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Atkins Diet
Description: Patients are given an outline of the Atkins diet and are asked to follow it for 6 months
Study: NCT02819089

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine
Description: Demedetomidine infusion (2mcg/ml); loading 0.5 mcg/kg for 30 min (BW/2 ml/h for 30 min), then 0.5 mcg/kg (BW/4 ml/h) until 30 minutes before finish the operation.
Study: NCT03268941

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-906 Maleate
Description: TAK-906 Maleate Capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-906 Maleate
Description: TAK-906 Maleate Capsules

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metaclopramide
Description: Metaclopramide Tablets

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: TAK-906 Maleate Placebo
Description: TAK-906 placebo-matching Capsules
Study: NCT03664804

Intervention type: OTHER
Group type: OTHER
Intervention: No Study Drug was Administered in this Study
Description: No study drug was administered in this study
Study: NCT04219254

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI1206
Description: BI-1206 administrated either IV or SC every third week. Pembrolizumab 200mg administered IV every third week as a fixed dose will be used in Phase 1 and IIa.~The mTPI2 Design will be used for both the IV and SC cohorts. ivRP2D and scRP2D to be used in Phase
Study: NCT02819089

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: NSS
Description: NSS infusion; loading BW/2 ml/h for 30 min, then BW/4 ml/h until 30 minutes before finish the operation.
Study: NCT01742897

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TTS-fentanyl
Study: NCT02431377

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: S-26 Gold
Description: A commercial whey protein dominant, first age formula, containing whey protein concentrate with alpha-lactalbumin
Study: NCT03188224

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MyTransition app
Description: MyTransition app is designed to support youth moving from pediatric to adult healthcare.
Study: NCT00801567

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Magnetic resonance spectroscopy (MRS)
Description: 90-minute magnetic resonance scan.
Study: NCT03196336

Intervention type: OTHER
Group type: OTHER
Intervention: Pharmacotherapy follow-up care
Description: The pharmacotherapy follow-up care consists of five pharmaceutical consultations (every up to 2-3 months) aimed to identify, prevent and solve the drug related problems regarding the indication, effectiveness and safety of the use of medicines.
Study: NCT03749772

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Training
Description: The intervention was carried out with the PC game Brain Exercise TM (Bandai Namco Games Ltd.). Participants held the training sessions on an HP 250 G3 Notebook PC (Windows 10), with a 15-inch screen, and a resolution of 1366x768x40 Hz. The performance achieved by each participant in each session was recorded to analyze the evolution of the subjects. The participants made a total of 12 practice exercises, which implies approximately 30 minutes of duration per session.
Study: NCT00214916

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: intensive insulin therapy (Actrapid IV to normoglycemia)
Description: intensive insulin therapy (Actrapid IV in continuous infusion to age-dependent normoglycemia)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: conventional insulin therapy (Actrapid IV only for excessive hyperglycemia)
Description: conventional insulin therapy (Actrapid IV in continuous infusion only to treat blood glucose levels exceeding 220 mg/dl)
Study: NCT03775746

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clopidogrel 75Mg Tablet
Description: Prevention of atherothrombotic events in percutaneous coronary intervention (adjunct with aspirin) in patients not already on clopidogrel

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clopidogrel 75Mg Tablet
Description: Prevention of atherothrombotic events in percutaneous coronary intervention (adjunct with aspirin) in patients not already on clopidogrel

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rivaroxaban 2.5Mg Tablet
Description: Prophylaxis of atherothrombotic events following an acute coronary syndrome with elevated cardiac biomarkers (in combination with aspirin alone or aspirin and clopidogrel)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ticagrelor 90Mg Tablet
Description: Prevention of atherothrombotic events in patients with acute coronary syndrome \[in combination with aspirin\]
Study: NCT02566590

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NMES
Description: device is used to stimulate muscle contraction in the legs of the patient. The intervention will be used 3 times a day during bed rest.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Protein
Description: supplement will used to enhance muscle anabolism. The intervention will be provided 3 times a day during bed rest.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: non-protein placebo supplement
Description: supplement will be used as a placebo to control participants. The supplement will be provided 3x a day during bed rest.
Study: NCT03878758

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BD Nano™ PRO
Description: Insulin Pen needle

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BD Nano™ PRO
Description: Insulin Pen needle

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BD Nano™ PRO
Description: Insulin Pen needle

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 33G Artsana Insupen Extr3me
Description: Insulin Pen Needle

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 34G Artsana Insupen Extr3me
Description: Insulin Pen Needle

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Simple Diagnostics Comfort EZ™
Description: Insulin Pen Needle
Study: NCT02506023

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Desmopressin
Description: Desmopressin or DDAVP will be administered intravenously (IV) via a nontraumatic peripheral IV line at a dose of 0.3 mcg/kg over 30 minutes.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Desmopressin
Description: Desmopressin or DDAVP will be administered intravenously (IV) via a nontraumatic peripheral IV line at a dose of 0.3 mcg/kg over 30 minutes.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Desmopressin
Description: Desmopressin or DDAVP will be administered intravenously (IV) via a nontraumatic peripheral IV line at a dose of 0.3 mcg/kg over 30 minutes.
Study: NCT01728844

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: beta-tricalcium phosphate alone

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: GFeBGS 0.1%
Study: NCT01831674

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin Hydrochloride Extended-Release Tablets USP 750
Description: Metformin Hydrochloride Extended-Release Tablets 750 mg once a day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin Hydrochloride Extended-Release Tablets USP 750
Description: Metformin Hydrochloride Extended-Release Tablets 750 mg once a day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GLUCOPHAGE®XR tablet 750 mg
Description: GLUCOPHAGE®XR 750 mg once a day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GLUCOPHAGE®XR tablet 750 mg
Description: GLUCOPHAGE®XR 750 mg once a day
Study: NCT04802187

Intervention type: OTHER
Group type: OTHER
Intervention: RADx CHCs testing intervention strategy
Description: The study team will support partner CHCs to implement workflows with some combination of dedicated testing staff, off-site testing, outreach/communications to priority populations, and linkage with local contact tracing systems. Implementation support will take the form of practice facilitation, rapid cycle testing (by supporting CHCs to review their internal data to assess the impact of workflow changes), and expert consultation from the research team on testing technology and testing location design.

Intervention type: OTHER
Group type: OTHER
Intervention: Usual care control
Description: CHCs implement testing strategies in accordance with their usual supports.
Study: NCT00317304

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness-based stress reduction
Description: MBSR is an 8-week group-based program of training in mindfulness and its application to the stresses and challenges of everyday life
Study: NCT00119366

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: iodine I 131 monoclonal antibody BC8
Description: Given IV

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: iodine I 131 monoclonal antibody BC8
Description: Given IV

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: iodine I 131 monoclonal antibody BC8
Description: Given IV

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: iodine I 131 monoclonal antibody BC8
Description: Given IV

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: iodine I 131 monoclonal antibody BC8
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fludarabine phosphate
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fludarabine phosphate
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fludarabine phosphate
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fludarabine phosphate
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fludarabine phosphate
Description: Given IV

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: total-body irradiation
Description: Undergo TBI
Study: NCT02363465

Intervention type: OTHER
Intervention: Echographic measurement of skin thickness
Description: (Epi)Dermal thickness at the proximal forearm and the deltoid region will be measured using imaging technology, more specifically high-frequency ultrasound (20-40 MHz) in B-mode (VEVO 2100®, Visual Sonics). This non-invasive measuring technique has already been proven to be accurate.~The echographic measurement will be performed on the left and right deltoid region and on two sides of the proximal forearm. Both the dorsal part and the volar/palmar part of the proximal forearm will be investigated. Ultrasound will be executed using gel (Aquasonic®) to optimize imaging.
Study: NCT01728844

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: GFeBGS 0.3%

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: GFeBGS 0.4%
Study: NCT03956940

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intplex test
Description: Blood sample at baseline, 15 days, 4-8-16 weeks and then every 12 weeks
Study: NCT03438994

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Play.Care
Description: iPad based game to assess movement as the player interacts with the screen

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Play.Care
Description: iPad based game to assess movement as the player interacts with the screen

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Play.Care
Description: iPad based game to assess movement as the player interacts with the screen
Study: NCT03886298

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: radiofrequency splanchnic denervation
Description: the authors will denervate the splanchnic nerves via radiofrequency
Study: NCT04392648

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Dexamethasone tablets orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Dexamethasone tablets orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Dexamethasone tablets orally.
Study: NCT03886298

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: retrocrural celiac denervation
Description: the authors will denervate the splanchnic nerves in the retrocrural space via injection of alcohol
Study: NCT00233948

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nelfinavir mesylate
Description: Given orally

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: biopsy
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative studies
Study: NCT00119366

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: total-body irradiation
Description: Undergo TBI
Study: NCT00233948

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: gene expression analysis
Description: Correlative studies

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: western blotting
Description: Correlative studies

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: reverse transcriptase-polymerase chain reaction
Description: Correlative studies